AlloCure is poised to become the first company to commercialize effective cell therapies to treat various kidney diseases, organ transplants, multi-organ injury and a number of other difficult to treat diseases. AlloCure has developed a proprietary process to manufacture cells derived from bone marrow which can be used in an allogeneic (does not require tissue matching of donor and recipient) or off-the-shelf setting. AlloCure's technology has multiple therapeutic applications which have the potential to effectively address many large medical markets.

AlloCure is dedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure’s unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases.

AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt lake City Utah and Hamburg Germany.